Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies.

Area of Science:

• Neuroscience
• Biochemistry
• Immunology

Background:

• Alzheimer's disease (AD) pathogenesis is linked to toxic soluble oligomers of amyloid-beta 1-42 (Aβ1-42), not senile plaques.
• These toxic species form early in Aβ1-42 aggregation or are released from fibrils.
• Current diagnostic and therapeutic tools for AD remain insufficient.

Purpose of the Study:

• To investigate the principles driving toxicity in AD by integrating in vitro immunochemical assays with in vivo neuronal models.
• To understand and target toxic soluble oligomers implicated in AD pathogenesis.

Main Methods:

• Utilized in vitro immunochemical assays and in vivo neuronal models of toxicity.
• Evaluated the specificity and sensitivity of A11 and OC conformational antibodies against various amyloid conformers.
• Assessed the ability of antibodies to rescue cytotoxic effects in neuronal culture models.

Main Results:

• Conformational antibodies demonstrated specificity for pathologically relevant Aβ1-42 oligomers and fibrils.
• These antibodies successfully prevented the detrimental effects of toxic assemblies on neuronal cells.
• Antibody treatment showed efficacy in rescuing neuronal function in cellular models.

Conclusions:

• Toxic amyloid assemblies play a crucial role in neurodegenerative diseases like AD.
• Conformational antibodies represent promising tools for both early diagnosis and targeted therapy in AD.
• This research advances the understanding of AD pathogenesis and paves the way for novel therapeutic interventions.